Symposium

[SY24] Symposium 24　Developments in the treatment of soft tissue sarcoma
【SI】【E】

Sat. Feb 19, 2022 10:00 AM - 11:30 AM Room 3 (Annex 2, 1F, Kyoto International Conference Center)

Chair：Shunji Takahashi（Department of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research），Suzanne George（Department of Medical Oncology, Dana-Farber Cancer Institute）

+Add all to schedule

[SY24-1] MASTER KEY Project: A platform study for rare cancers in Japan and Asia

^○Hitomi Okuma (Department of International Clinical Development, National Cancer Center Hospital)

[SY24-2] Possibility of immune checkpoint inhibitor as the new treatment strategy in the management of cutaneous angiosarcoma

^○Yasuhiro Fujisawa (Department of Dermatology, University of Tsukuba)

[SY24-3] A phase II study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma (NCCH1806/MK004)

^○Kazuki Sudo^1,2, Toshio Shimizu², Kan Yonemori^1,2, Takafumi Koyama², Naoko Matsui³, Masahisa Kamikura³, Sawako Tomatsuri³, Yuki Kojima¹, Hitomi Okuma¹, Tatsunori Shimoi¹, Emi Noguchi¹, Akihiko Hirakawa⁴, Ryo Sadachi³, Okita Natsuko³, Kenichi Nakamura³, Noboru Yamamoto², Yasuhiro Fujiwara^1,5 (1.Department of Medical Oncology, National Cancer Center Hospital, 2.Department of Experimental Therapeutics, National Cancer Center Hospital, 3.Clinical Research Support Office, National Cancer Center Hospital, 4.Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 5.Pharmaceutical and Medical Devices Agency)

[SY24-4] Recent developments in the treatment of soft tissue sarcoma: Using biology to drive rationale drug development

^○Suzanne George (Department of Medical Oncology, Dana-Farber Cancer Institute)